聯邦製藥(03933.HK)上半年純利增長27.0%至18.94億元 中期息每股16分
格隆匯8月29日丨聯邦製藥(03933.HK)公佈中期業績2025年上半年,公司收入爲人民幣75.19億元,同比上升4.8%;公司擁有人應佔期內溢利爲人民幣18.94億元,同比增長27.0%,基本每股盈利人民幣104.26分,擬派中期股息每股人民幣16.0分。
2025年上半年,中間體、原料藥及製劑產品的分部收入(包括分部間之銷售)分別爲人民幣23.04億元、人民幣29.99億元及人民幣39.79億元,較去年同期分別下降25.2%、下降23.4%及上升65.9%。中間體、原料藥及製劑產品的分部溢利分別爲人民幣6.35億元、人民幣2.51億元及人民幣15.06億元,較去年同期分別下降40.6%、下降52.0%及上升524.2%。
研發方面,集團共投入人民幣5.51億元用於藥品研發,研發費用同比上升14.9%。其中,費用化研發投入爲人民幣4.99億元,資本化研發投入爲人民幣5170萬元。集團已建立全面的研發體系,包括生物研發、化藥研發、創新藥研發、動保研發、臨牀研究及對外合作等多個平臺。集團開發中的人用藥新產品達43項,其中22項爲1類新藥,聚焦內分泌、代謝、自身免疫、眼科和抗感染等領域。動保開發中的新產品共61項,覆蓋寵物、畜類、禽類及水產。仿製藥質量和療效一致性評價及醫美等項目也在穩步推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.